Medically reviewed by Brendan Camp, MD Hidradenitis suppurativa (HS) is a chronic (long-term) condition that causes painful ...

It’s two years since Novartis got its Cosentyx IL-17 drug approved for the spinal disease ankylosing spondylitis, and the Swiss pharma company has new data that it hopes will allow it to compete ...

Secukinumab is under clinical development by Novartis and currently in Phase II for Unspecified Dermatological Disorders.

INR:1868. clt frozenfluffies Novartis Cosentyx first-line treatment: rapid and powerful clearance of skin lesions and improved quality of life Puli Pharmaceuti ...